Developing Recombinant Vaccines and Immunotherapy Strategies for Emerging Viral Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 37
Special Issue Editors
Interests: gene transcription in oxygen biology; autophagy; ubiquitin-proteosome system; cell signaling; influenza virus; dengue virus; program cell death; epigenetics; drug discovery and development; chemical biology
Special Issues, Collections and Topics in MDPI journals
Interests: mechanisms of resistance to antimicrobials; respiratory viruses; coronaviruses; laboratory diagnosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Emerging viral infections continue to pose serious global health hazards, frequently resulting in extensive epidemics with limited therapeutic options. The fast development and adaptation of viruses emphasizes the critical need for novel ways to prevent and treat them. To this end, recombinant vaccination technologies and enhanced immunotherapy tactics have emerged as promising approaches to overcoming these obstacles.
This Special Issue aim to highlight innovative studies and reviews which focus on the development of recombinant vaccines and newly developed immunotherapeutic treatments for re-emerging viral infections. Topics of interest include novel vaccine platforms (such as viral vectors, DNA/RNA-based vaccines, and protein subunit vaccines), advancements in antibody therapies, immune modulation techniques, and strategies for enhancing vaccine efficacy against highly mutable viruses.
Dr. Emmanuel Datan
Prof. Dr. Athanasios Tsakris
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- emerging viral diseases
- recombinant vaccines
- immunotherapy
- vaccine development
- immune modulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
